Integra LifeSciences (IART) Misses Q3 EPS by 2c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Wells Fargo Downgrades Integra LifeSciences (IART) to Market Perform
October 30, 2017 12:29 AM EDTWells Fargo downgraded Integra LifeSciences (NASDAQ: IART) from Outperform to Market Perform with a price target of $46.00.
The analyst believes the company organic growth will come in below the industry average over the coming 12 months on the heels of fresh competition, the acquisition... More
JPMorgan Downgrades Integra LifeSciences (IART) to Neutral
October 27, 2017 4:41 AM EDTJPMorgan downgraded Integra LifeSciences (NASDAQ: IART) from Overweight to Neutral with a price target of $44.00 (from $58.00).
Analyst Robbie Marcus cites a deteriorating base business and lowered growth outlook for the downgrade. The analyst fails to see a justification for a premium anymore noting growth degradation... More
